Severe coronavirus disease-2019 (COVID-19) is frequently associated with microvascular thrombosis, especially in the lung, or macrovascular thrombosis, mainly venous thromboembolism, that significantly contribute to the mortality burden of the disease.
COVID-19 patients also exhibit laboratory abnormalities compatible with a prothrombotic state. The key event underlying COVID-19-associated thrombotic complications is an excessive host inflammatory response to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection triggering the release of multiple inflammatory mediators, mainly cytokines and complement activation products.
The aim of this Webinar of the European and Mediterranean League Against Thrombotic Disease (EMLTD)is to provide an update, in the context of the rapidly evolving picture of the pandemia, on the role of thrombosis in the severity and outcomes of the disease, in order to improve both preventive and therapeutic strategies.
From “real life” epidemiological data to the biological background of the vascular and hemostatic system involvement, from the management of a complex clinical condition to the available evidence of an impact of anticoagulation on COVID-19 mortality, the different contributions will build a fascinating puzzle completed by the widely discussed vaccine… enigma, which again is calling thrombosis experts to apply their experience and extend their research.
July 1st 2021 · 15:00 - 17:00 CET
Chairmen: G.Degaetano ( IRCCS Neuromed, Italy) & A. Tselepis (University of Ioannina, Greece)
|15:00 - 15:05||
A. Tselepis & G. Degaetano
|15:05 - 15:10||
M. B. Donati (Italy)
IRCCS Neuromed, Pozzilli
|15:10 - 15:25||
Thrombosis in Covid-19 patients- Real World Data
J. Morais (Portugal)
Leiria Hospital Center
|15:25 - 15:40||
COVID-19: a “vascular” disease?
L. Badimon (Spain)
IR-Hospital de La Santa Creu I Sant Pau
|15:40 - 15:55||
Clinical audit of thrombotic risk in COVID-19 patients
I. Elalamy (France)
Tenon Hospital Medicine Sorbonne University Paris And Inserm Umrs 938
|16:10 - 16:25||
Heparin treatment and reduced in-hospital mortality of COVID-19 patients
L. Iacoviello (Italy)
IRCCS Neuromed, Pozzilli and University of Insubria, Varese
|16:25 - 16:40||
SARS-CoV-2 vaccine and thrombotic thrombocytopenia
V. Pengo (Italy)
University Hospital of Padova
|16:40 - 17:00||General Discussion and Conclusions|